Literature DB >> 17170622

The primary care of Alzheimer disease.

Craig D Rubin1.   

Abstract

Alzheimer disease is the most common cause of progressive irreversible intellectual loss in aging humans. The number of individuals and families affected by this disorder will continue to grow as society ages worldwide. Our understanding of the biology, underlying pathophysiology, and diagnosis of Alzheimer disease has greatly expanded over the past few years and much has been published in these areas. This review focuses on the primary care of this disorder and addresses the "now what" question. Topics examined include limiting excess disability, responding to commonly raised questions of family members, pharmacologic and nonpharmacologic therapeutic options, long-term planning, and caregiver issues.

Entities:  

Mesh:

Year:  2006        PMID: 17170622     DOI: 10.1097/00000441-200612000-00004

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  2 in total

1.  Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper.

Authors:  F Nourhashémi; M G Olde Rikkert; A Burns; B Winblad; G B Frisoni; J Fitten; B Vellas
Journal:  J Nutr Health Aging       Date:  2010-02       Impact factor: 4.075

Review 2.  Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.

Authors:  Lily P H Yang; Gillian M Keating
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.